A phase 1B/2 study of aldoxorubicin in patients with soft tissue sarcoma. - Wikidata - wikimedia - TriplyDB

A phase 1B/2 study of aldoxorubicin in patients with soft tissue sarcoma.

A phase 1B/2 study of aldoxorubicin in patients with soft tissue sarcoma.

http://www.wikidata.org/entity/Q34443422

about

Update on clinical research and state of the art management of patients with advanced sarcomas and GIST Albumin-Oxanorbornadiene Conjugates Formed ex Vivo for the Extended Circulation of Hydrophilic Cargo Current and advancing systemic treatment options for soft tissue sarcomas.Histology-Driven Therapy: The Importance of Diagnostic Accuracy in Guiding Systemic Therapy of Soft Tissue Tumors.The importance of drug metabolites synthesis: the case-study of cardiotoxic anticancer drugs.A novel individual-cell-based mathematical model based on multicellular tumour spheroids for evaluating doxorubicin-related delivery in avascular regions.Aldoxorubicin for the treatment of soft tissue sarcoma.Aldoxorubicin: a tumor-targeted doxorubicin conjugate for relapsed or refractory soft tissue sarcomas.

P2860

Q28073290-6F4B6926-D80A-47F3-8DAE-C3DDF8654DC5 Q38437371-3EDBC493-BB60-46A7-AC21-C055AF8CFEA3 Q38563242-D3456EBF-EEB3-40BA-9983-71A124A7956E Q38591828-58AAE1DA-088B-43D7-B948-6EB9A5FBA940 Q39231153-F98FB74F-2815-4EDB-B9DF-16D3A3F84CB4 Q47804226-27D5C4AC-4DFB-466F-A1C4-574CEA885ECD Q51800070-BAA170F0-FB07-4AB2-BD57-B1ED00DBF78B Q55092685-7EE90D00-8FB5-46CB-843B-E798A940F565

P2860

A phase 1B/2 study of aldoxorubicin in patients with soft tissue sarcoma.

http://www.wikidata.org/entity/Q34443422

description

2014 nî lūn-bûn

@nan

2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

name

A phase 1B/2 study of aldoxorubicin in patients with soft tissue sarcoma.

@ast

A phase 1B/2 study of aldoxorubicin in patients with soft tissue sarcoma.

@en

A phase 1B/2 study of aldoxorubicin in patients with soft tissue sarcoma.

@nl

type

label

A phase 1B/2 study of aldoxorubicin in patients with soft tissue sarcoma.

@ast

A phase 1B/2 study of aldoxorubicin in patients with soft tissue sarcoma.

@en

A phase 1B/2 study of aldoxorubicin in patients with soft tissue sarcoma.

@nl

prefLabel

A phase 1B/2 study of aldoxorubicin in patients with soft tissue sarcoma.

@ast

A phase 1B/2 study of aldoxorubicin in patients with soft tissue sarcoma.

@en

A phase 1B/2 study of aldoxorubicin in patients with soft tissue sarcoma.

@nl

P1433

Q34443422-629105B0-6800-4835-A1E4-8387D31A7C16

P1476

Q34443422-A3F0A48F-E0F9-43ED-AC20-8B9ACF647AA3

P2093

Q34443422-21E00FE7-8F9A-4E07-9F49-9C9FF71D341D

Q34443422-26B189FB-6BDA-467A-9DD6-46AD81F598CE

Q34443422-3D16A022-9E2A-4CAA-9CAD-AF884A540A78

Q34443422-6E3A6FE9-349B-4009-BAC4-E817F6223C72

Q34443422-7908C666-6F45-454F-83A0-EB7FB4F9570E

Q34443422-89E4D7D0-62D5-4225-A42E-859C3A36AACB

Q34443422-B493BDB3-3191-485F-B2DE-42DF5DB9F3C4

Q34443422-B82EEAAB-6010-4444-8F68-B8EE8BD2C9FE

P2860

Q34443422-27CEBE86-88E8-4ED0-A4AC-1AF0C42C922A

Q34443422-46863373-63FA-41E6-9174-A7EA563E09C1

Q34443422-6456EB55-A0E6-40B5-A3BF-3D7C147F3AF0

Q34443422-6ABEC4B8-427F-4A81-AD09-24C1D79776AB

Q34443422-6E014DD5-4FE7-4B9D-8293-F8355D13F8D5

Q34443422-6E0AE428-1104-4037-97CB-C1A0D42405D7

Q34443422-828B1461-B1FD-470F-8908-1154966D05DA

Q34443422-B2B18887-7A46-49B2-BE4D-9BDD38BE2FE3

Q34443422-C61C3E76-BC5D-4F3E-8171-0D81A92B89C6

Q34443422-D1B13DF2-55AE-4C21-BDB7-51BD59F77E9D

P304

Q34443422-59ECC636-3A89-4D3A-917A-332BEA306452

P31

Q34443422-B7CF7339-A0BF-4168-A40F-C4EF2914FE2B

P356

Q34443422-D4CEA79F-0AA8-4616-8237-E56630AFAD1F

P407

Q34443422-975EC38E-5249-44D9-A304-6677F7AA7099

P433

Q34443422-FFCBC649-0FF7-474D-8596-8EA21A2A46AC

P478

Q34443422-1849DD47-94BF-4CCC-ADB6-8A9B5149B3C1

P577

Q34443422-8324CF7C-6020-493F-A150-1ABF10B05B5D

P698

Q34443422-A599C64C-BC9E-45FE-A801-16ED584DA2EE

P356

P1433

P1476

A phase 1B/2 study of aldoxorubicin in patients with soft tissue sarcoma.

@en

P2093

Andrew F Hendifar

http://www.w3.org/2001/XMLSchema#string

D Scott Wieland

http://www.w3.org/2001/XMLSchema#string

Daniel J Levitt

http://www.w3.org/2001/XMLSchema#string

Doris V Quon

http://www.w3.org/2001/XMLSchema#string

Kamalesh K Sankhala

http://www.w3.org/2001/XMLSchema#string

Neelesh Soman

http://www.w3.org/2001/XMLSchema#string

Sant P Chawla

http://www.w3.org/2001/XMLSchema#string

Victoria S Chua

http://www.w3.org/2001/XMLSchema#string

P2860

Risk factors for doxorubicin-induced congestive heart failure

Dose response evaluation of adriamycin in human neoplasia

Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood

Optimizing clinical care in patients with advanced soft tissue sarcoma: a phase II study of a new schedule of high-dose continuous infusion ifosfamide and doxorubicin combination.

A clinicopathologic analysis of adriamycin cardiotoxicity.

Efficacy of first-line doxorubicin and ifosfamide in myxoid liposarcoma.

Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles.

Plasma protein (albumin) catabolism by the tumor itself--implications for tumor metabolism and the genesis of cachexia.

Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer.

Probing the cysteine-34 position of endogenous serum albumin with thiol-binding doxorubicin derivatives. Improved efficacy of an acid-sensitive doxorubicin derivative with specific albumin-binding properties compared to that of the parent compound.

P304

570-579

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CNCR.29081

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

121

http://www.w3.org/2001/XMLSchema#string

P577

2014-10-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25312684

http://www.w3.org/2001/XMLSchema#string